The mechanisms through which GBM cells evade GD2-targeted CAR-T and CAR-iNKT cells effectively target GBM but are susceptible to repeated antigen exposure, which IL-12 could counteract, and encourage further development of armored IL-12 CAR-T or CAR-iNKT cells.
Abstract
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by rapid progression and a poor prognosis. CAR-based cellular therapies are promising approaches, and CAR-T cells targeting GD2 have demonstrated transient efficacy. Identifying how tumors evade these treatments is essential for advancing therapy development. In this study, we investigated the mechanisms through which GBM cells evade GD2.chimeric antigen receptor (CAR)-T and CAR-invariant natural killer T (iNKT) in vitro and explored ways to overcome tumor escape. GD2-targeted CAR-T and CAR-iNKT cells were tested in a stepwise in vitro model that repeatedly exposed them to GD2+ cell lines. While CAR effector cells effectively killed GD2+ GBM cells in short-term assays, their anti-tumor efficacy declined after repeated antigen exposures. Tumor escape mechanisms included reduced CAR expression, impaired proliferation, reduced production of cytokine, granzyme, and perforin, tumor downregulation of GD2, trogocytosis, and upregulation of the HLA-E/NKG2A inhibitory compared to MICA-B/NKG2D activation pathways on tumor and immune cells. Increasing effector cell numbers or adding IL-15 ± IL-7 partially improved CAR persistence but did not fully restored CAR effector functions. By contrast, IL-12 addition optimized tumor-killing capacity by increasing CAR effector cell proliferation, CAR surface expression, IFN-γ production and balancing HLA-E/NKG2A versus MICA-B/NKG2D pathways. In conclusion, GD2.CAR-T and GD2.CAR-iNKT cells effectively target GBM but are susceptible to repeated antigen exposure, which IL-12 could counteract. These findings encourage further development of armored IL-12 CAR-T or CAR-iNKT cells and further investigation of the roles of HLA-E and MICA-B pathways in immunotherapy against GBM.
It is demonstrated that NKG2D-targeted third-generation CAR-T EVs exert combined anti-HCC activities through direct tumor cytotoxicity and restoration of NK cell function, providing a novel immunotherapeutic strategy for HCC.
Zhi-Feng Zhou, Hui-Ling Wu, Shen Zhao et al.· Frontiers in Immunology· 0 citations
Background: Chimeric antigen receptor (CAR) T-cell therapy for solid tumors is limited by inadequate T-cell persistence and tumor infiltration, as well as treatment-associated cytokine release syndrome (CRS). To address these challenges, we developed a metabolically rewired CAR T-cell (MRCAR) platform by co-expressing...
Yue Hu, Kevin Song, Ruo-Ning Wang et al.· Biomedicines· 0 citations
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
Chimeric antigen receptor (CAR)-T cell therapy has limited efficacy in solid tumors like esophageal squamous cell carcinoma (ESCC). This study investigates whether combining CAR-T cells with an anti-PD-1 antibody can overcome immunosuppression and impr...
In the SKOV3-A2 solid tumor xenograft model, WT1-CAR-Nb T cells mediated superior tumor growth control and significantly prolonged overall survival, which was closely correlated with enhanced intratumoral T cell infiltration and persistent in vivo expansion of engineered T cells.
Wan-Jun He, Kai Cui, Yi-Wei Zeng et al.· Journal of Translational Med...· 0 citations
It is indicated that no single engineering strategy is sufficient to overcome the interconnected barriers of GBM, and future progress in GBM CAR therapy will therefore depend on combining complementary solutions rather than improving only one CAR feature.
Aleksandra Królikowska, Katarzyna Białkowska· International Immunopharmaco...· 0 citations
Chimeric Antigen Receptor T (CAR-T) cell therapy has emerged as a promising therapeutic option, particularly for refractory and relapsed leukemias. However, its efficacy in treating solid tumors, including lung, ovarian, gastric, and breast cancers, remains limited by several challenges. Recent studies have highlighted...
Qian Niu, Meng Li, Cheng-Yi Zhang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.